The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
cSCC is one of the most common cancers in the U.S. and globally
NewCo’s pipeline includes five investigational medicines
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Imfinzi also recommended for patients with mismatch repair deficient disease
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
